Jakafi (Incyte) is expected to face US generic competition from 2028. Incyte 10-K: estimated minimum US market exclusivity 2028, when the composition patents expire. Jakafi is 60% of Incyte's revenue.
Jakafi's US exclusivity date is based on company guidance. The date comes from the company's own filings or guidance. Secondary patents, new formulations or litigation can still move it. It is a small-molecule drug, so copies are generics. Generic launches usually take most of the US volume within months.
Among past small-molecule drugs facing generics: Tecfidera's US sales fell to 21% of their 2019 level in its first full year of generics (2021); Revlimid's US sales fell to 96% of their 2021 level in its first full year of generics (2022) and 57% two years later. Where settlements cap generic volumes, as with Revlimid, the decline is slower. See how past cliffs played out →
Filed with the FDA Nine companies have challenged Jakafi's patents, which expire in June and December 2028. Incyte has settled with five on confidential terms; the other cases are pending.
| Company (product) | Stage |
|---|---|
| Hikma, Granules, Dr. Reddy's, Eugia, Alkem | Settled, terms confidential |
| Apotex, Sun, Alembic, MSN | In litigation |
Checked September 2026. Sources: Incyte 10-K 2025 · Incyte 10-Q, Q2 2026
Jakafi is 60% of Incyte's 2025 revenue ($3.1B of $5.1B).
Bars show each company's tracked drugs as a share of its total 2025 revenue. Jakafi is highlighted.